EP0973513A4 - Compositions et methodes pour traiter les etats associes a un deficit osseux - Google Patents

Compositions et methodes pour traiter les etats associes a un deficit osseux

Info

Publication number
EP0973513A4
EP0973513A4 EP97912787A EP97912787A EP0973513A4 EP 0973513 A4 EP0973513 A4 EP 0973513A4 EP 97912787 A EP97912787 A EP 97912787A EP 97912787 A EP97912787 A EP 97912787A EP 0973513 A4 EP0973513 A4 EP 0973513A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
treating bone
deficit conditions
bone deficit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97912787A
Other languages
German (de)
English (en)
Other versions
EP0973513A1 (fr
Inventor
Mark W Orme
Nand Baindur
Kirk G Robbins
Scott M Harris
Maria Kontoyianni
Laurence H Hurley
Sean M Kerwin
Gregory R Mundy
Charles Petrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
OsteoScreen Inc
University of Texas System
Original Assignee
Zymogenetics Inc
OsteoScreen Inc
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, OsteoScreen Inc, University of Texas System filed Critical Zymogenetics Inc
Publication of EP0973513A1 publication Critical patent/EP0973513A1/fr
Publication of EP0973513A4 publication Critical patent/EP0973513A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP97912787A 1996-10-23 1997-10-23 Compositions et methodes pour traiter les etats associes a un deficit osseux Withdrawn EP0973513A4 (fr)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US73587496A 1996-10-23 1996-10-23
US73587396A 1996-10-23 1996-10-23
US73622096A 1996-10-23 1996-10-23
US73631996A 1996-10-23 1996-10-23
US73631896A 1996-10-23 1996-10-23
US73622196A 1996-10-23 1996-10-23
US73588196A 1996-10-23 1996-10-23
US73587096A 1996-10-23 1996-10-23
US73587696A 1996-10-23 1996-10-23
US73622296A 1996-10-23 1996-10-23
US73622896A 1996-10-23 1996-10-23
US736228 1996-10-23
US735870 1996-10-23
US736319 1996-10-23
US735881 1996-10-23
US735874 1996-10-23
US736220 1996-10-23
US736318 1996-10-23
US736221 1996-10-23
US735876 1996-10-23
US736222 1996-10-23
US735873 1996-10-23
PCT/US1997/018864 WO1998017267A1 (fr) 1996-10-23 1997-10-23 Compositions et methodes pour traiter les etats associes a un deficit osseux

Publications (2)

Publication Number Publication Date
EP0973513A1 EP0973513A1 (fr) 2000-01-26
EP0973513A4 true EP0973513A4 (fr) 2003-03-19

Family

ID=27582807

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97912787A Withdrawn EP0973513A4 (fr) 1996-10-23 1997-10-23 Compositions et methodes pour traiter les etats associes a un deficit osseux

Country Status (4)

Country Link
EP (1) EP0973513A4 (fr)
JP (1) JP2001510450A (fr)
AU (1) AU4988997A (fr)
WO (1) WO1998017267A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008208A (en) 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
AU706262B2 (en) * 1995-10-23 1999-06-10 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6303645B1 (en) 1998-05-22 2001-10-16 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6369091B1 (en) 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
CA2332989A1 (fr) 1998-05-22 1999-12-02 Avanir Pharmaceuticals Derives benzimidazoles utilises en tant que modulateurs d'ige
WO1999065897A1 (fr) * 1998-06-19 1999-12-23 Chiron Corporation Inhibiteurs de glycogene synthase kinase 3
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
NZ513487A (en) 1999-01-29 2003-02-28 Univ Illinois The use of a P53 inhibitor for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant
AU782353B2 (en) * 1999-03-26 2005-07-21 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
AU5250400A (en) * 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
WO2001017562A1 (fr) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
JP5278983B2 (ja) * 1999-11-17 2013-09-04 塩野義製薬株式会社 アミド化合物の新規用途
RU2268260C2 (ru) 2000-03-31 2006-01-20 Ниппон Синяку Ко., Лтд. Производные хиназолина или хинолина и лекарственные средства на их основе
RU2324686C2 (ru) * 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
DK1368028T3 (da) 2001-03-12 2007-12-27 Avanir Pharmaceuticals Benzimidazolforbindelser til IgE-modulering og inhibering af cellulær profi-ferering
JP4317955B2 (ja) 2001-04-23 2009-08-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア アミロイド斑凝集阻害剤および診断用造影剤
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
PL366799A1 (en) 2001-07-27 2005-02-07 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US7064139B2 (en) * 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
EP2324825A1 (fr) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylurées dotées d'une activité d'inhibition de l'angiogenèse
US8110587B2 (en) 2002-02-11 2012-02-07 Bayer Healthcare Llc Aryl ureas as kinase inhibitors
MXPA04010539A (es) 2002-04-26 2005-01-25 Nippon Shinyaku Co Ltd Derivados de quinazolina y medicamentos que los contienen.
SE0202134D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
US7247741B2 (en) 2005-01-21 2007-07-24 Ptc Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
CA2493457A1 (fr) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Composes d'acide acetylamino benzoique et leur utilisation pour la suppression de non-sens et le traitement de maladie
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
EP1558341A4 (fr) * 2002-11-01 2010-09-08 Paratek Pharm Innc Composes modulant le facteur de transcription et methodes d'utilisation de ces derniers
ATE384264T1 (de) 2003-05-20 2008-02-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe mit kinasehemmender wirkung
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
FR2860431A1 (fr) * 2003-10-02 2005-04-08 Oreal Composition capillaire ou de mascara contenant un compose azoique, son utilisation pour stimuler ou induire la pousse des cheveux ou des cils et/ou freiner leur chute
ITTO20040125A1 (it) * 2004-03-01 2004-06-01 Rotta Research Lab Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica
JP2008504233A (ja) 2004-04-23 2008-02-14 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
MXPA06012333A (es) 2004-04-30 2007-01-17 Takeda Pharmaceutical Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13.
EP2023720A4 (fr) * 2006-05-17 2009-06-10 Cylene Pharmaceuticals Inc Analogues d'imidazole tétracycliques
JP5186303B2 (ja) * 2008-07-31 2013-04-17 東京応化工業株式会社 レジスト組成物およびレジストパターン形成方法
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
JP5930205B2 (ja) 2010-08-26 2016-06-08 国立大学法人京都大学 多能性幹細胞の心筋分化促進剤
CN102558091B (zh) * 2011-12-22 2014-10-08 合肥工业大学 一种苯并噻唑类衍生物及其用途
EP2808383B1 (fr) * 2012-01-27 2018-07-25 Kyoto University Procédé d'induction de la différenciation cardiaque de cellules souches pluripotentes
US9388138B2 (en) 2012-07-18 2016-07-12 University College Dublin National University Of Ireland, Dublin Anti-angiogenic compounds
CN102942515A (zh) * 2012-10-22 2013-02-27 暨南大学 一种乙烯桥连吲哚化合物及其合成方法和用途
WO2014136519A1 (fr) 2013-03-08 2014-09-12 国立大学法人京都大学 Promoteur de différenciation d'une cellule souche pluripotente en myocarde, lequel comprend un inhibiteur d'un récepteur d'egf
EP3150705B1 (fr) 2014-05-30 2019-05-15 Kyoto University Procédé d'induction de la différenciation myocardique des cellules souches pluripotentes à l'aide d'un composé de faible poids moléculaire
CN106188003B (zh) * 2016-07-22 2019-01-22 清华大学深圳研究生院 基于喹啉骨架的Cu2+和Fe3+双靶点荧光探针及其制备方法和应用
CN112010846A (zh) * 2019-05-30 2020-12-01 四川大学华西医院 一种吡啶衍生物及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2058564A (en) * 1979-09-07 1981-04-15 Horton J E Pharmaceutical compositions comprising anti-osteoporotic agents
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
EP0740936A2 (fr) * 1995-05-05 1996-11-06 Adir Et Compagnie Utilisation des dérivés du benzopyrane pour l' obtention de compositions pharmaceutiques destinées au traitement des pathologies liées a l'énchangeur Cl-/HCO3-,Na+ indépendant
WO1997015308A1 (fr) * 1995-10-23 1997-05-01 Zymogenetics, Inc. Compositions et procedes pour le traitement des deficits osseux
EP0783888A1 (fr) * 1995-12-26 1997-07-16 Sankyo Company Limited Utilisation de la troglitazone et de thiazolidinediones apparentées dans la fabrication d'un médicament destiné au traitement et la prévention de l'ostéoporose
WO1997048694A1 (fr) * 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Composes et procedes d'obtention de preparations pharmacologiquement actives et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
US5523309A (en) * 1995-03-10 1996-06-04 Eli Lilly And Company Benzofuran pharmaceutical compounds
US5622974A (en) * 1995-03-10 1997-04-22 Eli Lilly And Company α-substituted-3-benzyl-benzofurans

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2058564A (en) * 1979-09-07 1981-04-15 Horton J E Pharmaceutical compositions comprising anti-osteoporotic agents
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
EP0740936A2 (fr) * 1995-05-05 1996-11-06 Adir Et Compagnie Utilisation des dérivés du benzopyrane pour l' obtention de compositions pharmaceutiques destinées au traitement des pathologies liées a l'énchangeur Cl-/HCO3-,Na+ indépendant
WO1997015308A1 (fr) * 1995-10-23 1997-05-01 Zymogenetics, Inc. Compositions et procedes pour le traitement des deficits osseux
EP0783888A1 (fr) * 1995-12-26 1997-07-16 Sankyo Company Limited Utilisation de la troglitazone et de thiazolidinediones apparentées dans la fabrication d'un médicament destiné au traitement et la prévention de l'ostéoporose
WO1997048694A1 (fr) * 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Composes et procedes d'obtention de preparations pharmacologiquement actives et leurs utilisations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198314, Derwent World Patents Index; AN 1983-33820k, XP002228668 *
RD-227016 A (10-03-1983) *
See also references of WO9817267A1 *

Also Published As

Publication number Publication date
WO1998017267A1 (fr) 1998-04-30
JP2001510450A (ja) 2001-07-31
AU4988997A (en) 1998-05-15
EP0973513A1 (fr) 2000-01-26

Similar Documents

Publication Publication Date Title
EP0973513A4 (fr) Compositions et methodes pour traiter les etats associes a un deficit osseux
EP0866710A4 (fr) Compositions et procedes pour le traitement des deficits osseux
GR20010300060T1 (en) Methods and compositions for treating and preventing mucositis
IL134205A0 (en) Phototherapy based method for treating pathogens and compositions for effecting same
IL129555A0 (en) Methods and compositions for stimulating neurite growth
IL115405A0 (en) Compositions and methods for treating mast-cell mediated conditions
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
ZA9710248B (en) Methods and compositions for stimulating neurite growth.
ZA9710258B (en) Methods and compositions for stimulating neurite growth.
HUP9900960A3 (en) Disinfecting compositions and method for disinfecting surfaces
EP0961613A4 (fr) Methodes et compositions pour le traitement des troubles de la resorption osseuse, y compris l&#39;osteoporose
HK1023371A1 (en) Compositions and methods for treating viral infections
EP0946158A4 (fr) Compositions et procede de bronzage de la peau
AU9214398A (en) Compositions and methods for treating water
EP1088333A4 (fr) Compositions et procedes inhibant la resorption osseuse
EP1109548A4 (fr) Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses
ZA981600B (en) Methods and compositions for treating stickies
GB9621570D0 (en) Formulations and methods for inhibiting bone loss
EP0769944A4 (fr) Procedes enrayant la degenerescence des protheses osseuses
IL111554A (en) Methods and compositions for hair treatment
AU5594398A (en) Methods and compositions for preventing and treating bone loss
EP0835092A4 (fr) Composition et traitement pour la lutte contre la calvitie
AU5791698A (en) Methods and compositions for preventing and treating bone loss
EP1089750A4 (fr) Compositions et procedes permettant d&#39;inhiber la resorption d&#39;un os
PL331283A1 (en) Preparation for treating and/or preventing stupefaction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEM

Owner name: OSTEOSCREEN, INC.

Owner name: ZYMOGENETICS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20030205

17Q First examination report despatched

Effective date: 20040909

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050120